The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) Study
Open accessAbstract
BACKGROUND. The risk of myocardial infarction (MI) in patients with human immunodeficiency virus (HIV) infection has been assessed in 13 anti-HIV drugs in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. METHODS. Poisson regression models were adjusted for cardiovascular risk factors, cohort, calendar year, and use of other antiretroviral drugs and assessed the association between MI risk and cumulative (per year) or recent (current or in the past 6 months) use of antiretroviral drugs, with >30,000 person-years of exposure. RESULTS. Over 178,835 person-years, 580 patients developed MI. There were no associations between use of tenofovir, zalcitabine, zidovudine, stavudine, or lamivudine and MI risk. Recent exposure to abacavir or didanosine was associated with an increased risk of MI. No association was found between MI risk and cumulative exposure to nevirapine, efavirenz, nelfinavir, or saquinavir. Cumulative exposure to indinavir and lopinavir-ritonavir was associated with an increased risk of MI (relative rate [RR] per year, 1.12 and 1.13, respectively). These increased risks were attenuated slightly (RR per year, 1.08 [95% confidence interval {CI}, 1.02-1.14] and 1.09 [95% CI, 1.01-1.17], respectively) after adjustment for lipids but were not altered further after adjustment for other metabolic parameters. CONCLUSIONS. Of the drugs considered, only indinavir, lopinavir-ritonavir, didanosine, and abacavir were associated with a significantly increased risk of MI. As with any observational study, our findings must be interpreted with caution (given the potential for confounding) and in the context of the benefits that these drugs provide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adjusting for multiple testing—when and how?
Bender, R., & Lange, S. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00314-0 · Cited by 3,004
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Self-citationCarr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., & Cooper, D. A. (1998) · AIDS · doi:10.1097/00002030-199807000-00003 · Cited by 2,370
Self-citationTunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A. M., & Pajak, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,263
An updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,678
Class of Antiretroviral Drugs and the Risk of Myocardial Infarction
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa062744 · Cited by 1,521
Gallant, J. E. (2004) · JAMA · doi:10.1001/jama.292.2.191 · Cited by 1,341
Friis-Møller, N., Weber, R., Reiss, P., Thiébaut, R., Kirk, O., Monforte, A. D., Pradier, C., Morfeldt, L., Mateu, S., Law, M., et al. (2003) · AIDS · doi:10.1097/00002030-200305230-00010 · Cited by 1,077
Self-citationHammer, S. M., Eron, J. J., Reiss, P., Schooley, R. T., Thompson, M. A., Walmsley, S., Cahn, P., Fischl, M. A., Gatell, J. M., Hirsch, M. S., et al. (2008) · JAMA · doi:10.1001/jama.300.5.555 · Cited by 1,026
Self-citationClass-Sparing Regimens for Initial Treatment of HIV-1 Infection
Riddler, S. A., Haubrich, R., DiRienzo, A. G., Peeples, L., Powderly, W. G., Klingman, K. L., Garren, K. W., George, T., Rooney, J. F., Brizz, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074609 · Cited by 680
Mulligan, K., Grunfeld, C., Tai, V. W., Algren, H., Pang, M., Chernoff, D. N., Lo, J. C., & Schambelan, M. (2000) · Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200001010-00005 · Cited by 518
Multiple Comparisons and Related Issues in the Interpretation of Epidemiologic Data
Savitz, D. A., & Olshan, A. F. (1995) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117737 · Cited by 459
Fontas, E., van Leth, F., Sabin, C. A., Friis‐Møller, N., Rickenbach, M., d’Arminio Monforte, A., Kirk, O., Dupon, M., Morfeldt, L., Mateu, S., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/381783 · Cited by 337
Self-citationvan Leth, F., Phanuphak, P., Stroes, E., Gazzard, B., Cahn, P., Raffi, F., Wood, R., Bloch, M., Katlama, C., Kastelein, J. J. P., et al. (2004) · PLoS Medicine · doi:10.1371/journal.pmed.0010019 · Cited by 276
Self-citationLedergerber, B., Furrer, H., Rickenbach, M., Lehmann, R., Elzi, L., Hirschel, B., Cavassini, M., Bernasconi, E., Schmid, P., Egger, M., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/518619 · Cited by 261
Self-citationPhillips, A. N., Carr, A., Neuhaus, J., Visnegarwala, F., Prineas, R., Burman, W. J., Williams, I., Drummond, F., Duprez, D., Belloso, W. H., et al. (2008) · Antiviral Therapy · doi:10.1177/135965350801300215 · Cited by 240
Self-citationArribas, J. R., Pozniak, A. L., Gallant, J. E., DeJesus, E., Gazzard, B., Campo, R. E., Chen, S.-S., McColl, D., Holmes, C. B., Enejosa, J., et al. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31815acab8 · Cited by 235
Chronic renal failure among HIV-1-infected patients
Mocroft, A., Kirk, O., Gatell, J., Reiss, P., Gargalianos, P., Zilmer, K., Beniowski, M., Viard, J.-P., Staszewski, S., & Lundgren, J. D. (2007) · AIDS · doi:10.1097/qad.0b013e3280f774ee · Cited by 228
Self-citationMetabolic Syndrome in HIV-Infected Patients from an Urban, Midwestern US Outpatient Population
Mondy, K., Overton, E. T., Grubb, J., Tong, S., Seyfried, W., Powderly, W., & Yarasheski, K. (2007) · Clinical Infectious Diseases · doi:10.1086/511679 · Cited by 213
The metabolic effects of lopinavir/ritonavir in HIV-negative men
Lee, G. A., Seneviratne, T., Noor, M. A., Lo, J. C., Schwarz, J.-M., Aweeka, F. T., Mulligan, K., Schambelan, M., & Grunfeld, C. (2004) · AIDS · doi:10.1097/00002030-200403050-00008 · Cited by 206
Renal safety of tenofovir in HIV treatment-experienced patients
Izzedine, H., Isnard-Bagnis, C., Hulot, J. S., Vittecoq, D., Cheng, A., Jais, C. K., Launay-Vacher, V., & Deray, G. (2004) · AIDS · doi:10.1097/00002030-200404300-00019 · Cited by 173
Glass, T., Ungsedhapand, C., Wolbers, M., Weber, R., Vernazza, P., Rickenbach, M., Furrer, H., Bernasconi, E., Cavassini, M., Hirschel, B., et al. (2006) · HIV Medicine · doi:10.1111/j.1468-1293.2006.00400.x · Cited by 156 · cited 1×
“MI Risk and Antiretroviral Therapy • JID 2010:201 (1 February) • 319 general population [1], although the situation has improved somewhat over the past few years [2, 3].”
BackgroundSelf-citationThe effect of low‐dose ritonavir monotherapy on fasting serum lipid concentrations
Shafran, S. D., Mashinter, L., & Roberts, S. (2005) · HIV Medicine · doi:10.1111/j.1468-1293.2005.00328.x · Cited by 151
Dragsted, U. B., Gerstoft, J., Pedersen, C., Peters, B. S., Duran, A. S., Obel, N., Castagna, A., Cahn, P. E., Clumeck, N., Bruun, J. N., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/377288 · Cited by 118
Self-citationAssociation of antiretroviral therapy with fibrinogen levels in HIV-infection
Madden, E., Lee, G., Kotler, D. P., WANKE, C. A., Lewis, C. E., Tracy, R. P., Heymsfield, S. B., Shlipak, M. G., Bacchetti, P., Scherzer, R., et al. (2008) · AIDS · doi:10.1097/qad.0b013e3282f560d9 · Cited by 78
Dubé, M. P., Shen, C., Greenwald, M., & Mather, K. J. (2008) · Clinical Infectious Diseases · doi:10.1086/590154 · Cited by 71
Data Collection on Adverse Events of Anti‐HIV Drugs Study Group (2008) · Clinical Infectious Diseases · doi:10.1086/528862 · Cited by 61
Franssen, R., Sankatsing, R. R., Hassink, E., Hutten, B., Ackermans, M., Brinkman, K., Oesterholt, R., Arenas-Pinto, A., Storfer, S., Kastelein, J., et al. (2009) · Arteriosclerosis, Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.192088 · Cited by 56
Self-citationTolerability and Safety of HIV Protease Inhibitors in Adults
Sax, P. E., & Kumar, P. N. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000138420.38995.86 · Cited by 52
León, A., Martínez, E., Sarasa, M., López, Y., Mallolas, J., de Lazzari, E., Laguno, M., Milincovic, A., Blanco, J. L., Larrousse, M., et al. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm285 · Cited by 13
Cited by
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Self-citationFihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,410
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.013 · Cited by 1,555
Hammer, S. M., Eron, J. J., Reiss, P., Schooley, R. T., Thompson, M. A., Walmsley, S., Cahn, P., Fischl, M. A., Gatell, J. M., Hirsch, M. S., et al. (2008) · JAMA · doi:10.1001/jama.300.5.555 · Cited by 1,026
Self-citationSmith, C. J., Ryom, L., Weber, R., Morlat, P., Pradier, C., Reiss, P., Kowalska, J. D., de Wit, S., Law, M., el Sadr, W., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60604-8 · Cited by 928
Self-citation
Metadata
- Authors
- Worm, S. W., Sabin, C., Weber, R., Reiss, P., El‐Sadr, W., Dabis, F., De Wit, S., Law, M., Monforte, A. D., Friis‐Møller, N., Kirk, O., Fontas, E., Weller, I., Phillips, A., & Lundgren, J.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-02
- Volume
- 201
- Issue
- 3
- Pages
- 318-330
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2167865974
- Cited by
- 648
- References
- 32
- FWCI
- 58.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.